BridgeBio Pharma BBIO Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| License and services revenue | $121.88M-11.3% | $137.36M— | —— | $76.09M+15.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does BridgeBio Pharma break its business down?
- BridgeBio Pharma (BBIO) reports revenue by product across 2 parts — Cost of license, services, and royalty revenue and License and services revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does BridgeBio Pharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BridgeBio Pharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
